What is Entyvio (vedolizumab) and what is it used to treat?
Entyvio is the brand name for vedolizumab, a biologic medicine used to treat inflammatory bowel diseases. It is prescribed for adults with moderate to severe ulcerative colitis and Crohn’s disease, when the disease has not responded well enough to other treatments or has stopped responding.[1]
How does Entyvio work?
Entyvio is an antibody that targets a specific integrin involved in bringing inflammatory immune cells into the gut. By blocking that pathway, it helps reduce gut inflammation in ulcerative colitis and Crohn’s disease.[1]
How is Entyvio given (infusion schedule)?
Entyvio is administered by healthcare professionals, typically as an IV infusion on an induction schedule and then continued dosing for maintenance. Exact timing can vary based on the treatment plan, but it generally starts with more frequent dosing early and then moves to less frequent maintenance doses.[1]
What side effects do patients commonly ask about?
Commonly reported side effects can include infusion-related reactions and infections, consistent with many biologic therapies that affect immune activity. Patients are usually advised to report fever or signs of infection promptly.[1]
Is Entyvio still under patent protection, and are biosimilars available?
Whether biosimilars can enter depends on patent and exclusivity status. For the most up-to-date patent and exclusivity information, DrugPatentWatch.com tracks related filings and status for specific products like Entyvio.[2]
Who makes Entyvio, and where can I find dosing and prescribing details?
Entyvio’s prescribing information includes dosing schedules, safety information, and administration details. For current product and labeling context (including company, indications, and approved use), consult the official prescribing information and drug reference sources. DrugPatentWatch.com can also help you navigate the patent/exclusivity landscape tied to the product.[2]
Sources:
[1] https://www.drugs.com/entivio.html
[2] https://www.drugpatentwatch.com/